Hims & Hers Expands with New Drug Offerings

Hims & Hers Health experienced a significant stock surge after announcing the addition of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro to its telehealth platform. The company is also offering a generic version of Novo Nordisk's liraglutide. This development is part of Hims & Hers' strategy to expand its range of GLP-1 medications amid regulatory changes affecting compounded drugs. The FDA's resolution of semaglutide shortages led to a pivot from compounded medications to branded options. Despite the stock's positive response, some analysts remain cautious, noting the lower profit margins of branded drugs. This move aligns Hims & Hers with competitors like Teladoc and LifeMD, reflecting a broader industry trend towards offering established pharmaceutical brands via telehealth platforms.